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CD95 is the quintessential death receptor and, when it is bound by ligand, cells undergo 
apoptosis. Recent evidence suggests, however, that CD95 mediates not only apoptosis 
but also diverse nonapoptotic functions depending on the tissue and the conditions.Introduction
Apoptosis is induced by a subgroup of 
the tumor necrosis factor (TNF) recep-
tor superfamily. These so-called death 
receptors include CD95 (Fas/APO-1), 
DR3, TNF-R1, and two TRAIL recep-
tors. A shared feature of death recep-
tors is a conserved 80 amino acid 
sequence, the death domain, in the 
cytoplasmic tail of these molecules. 
CD95 is a quintessential death recep-
tor that is constitutively expressed by 
most tissues. Upon ligation of CD95, 
sequential association of the adaptor 
molecule FADD (MORT1), pro-forms of 
caspases 8 and 10, and the caspase-
8/10 regulator c-FLIP lead to the for-
mation of a death-inducing signaling 
complex (DISC) (Peter and Krammer, 
2003). The resulting oligomerization 
of procaspase-8 results in its activa-
tion, autoproteolytic processing, and 
release of an active heterotetrameric 
enzyme into the cytosol. The ensu-
ing apoptotic program kills cells via 
two different pathways: either active 
caspase-8 directly cleaves and acti-
vates caspase-3 (type I) or caspase-3 
cleavage is induced indirectly (type II). 
Alternatively, CD95 can trigger a non-
apoptotic caspase-independent form 
of cell death (Holler et al., 2000).Although CD95 has been viewed 
primarily as a death-inducing recep-
tor, accumulating evidence suggests 
that ligation of CD95 can also medi-
ate a variety of nonapoptotic activities 
and that its proapoptotic role in lym-
phocytes, pancreas, liver, and brain 
may have been overstated. Thus, 
although ligation of CD95 may induce 
apoptosis in some cell types under 
certain conditions, it may also protect 
cells and regulate tissue regeneration 
and proliferation. Here, we discuss 
the activities and signaling pathways 
of CD95 that support the notion that 
CD95 is not merely a dedicated death 
receptor but behaves like other mem-
bers of the TNF receptor superfamily 
by mediating diverse functions in 
different tissues and under different 
conditions.
CD95: The Prototypic Death 
Receptor
The investigation of death receptors 
began with the isolation of agonistic 
CD95-specific monoclonal antibod-
ies that ligate CD95 at the cell sur-
face and induce apoptosis of cells 
from various tissues. An indication 
that CD95 is a proapoptotic mol-
ecule in vivo came from studies in Cell 12which mice injected with the CD95 
monoclonal antibody Jo2 exhibited 
massive apoptosis of liver cells. A 
primarily pro-death role for CD95 and 
its ligand, CD95L, in T cells was pos-
tulated based on the spontaneous 
development of autoimmune disease 
in three CD95/CD95L mutant mouse 
strains (Bidere et al., 2006). Autoim-
munity in these models is charac-
terized by massive accumulation of 
lymphocytes (primarily CD4− /CD8− /
B220+ T cells), production of high 
titer autoreactive antibodies, and var-
ious related pathologies. The gene 
mutation in the lpr (lymphoprolifera-
tion) mouse strain causes defective 
expression of CD95 due to insertion 
of a transposable element into intron 
2. The second mouse strain (gld, gen-
eralized lymphoproliferative disorder) 
expresses a mutant form of CD95L. 
The third mouse strain with an lpr-like 
phenotype (lprcg) has a point muta-
tion in the death domain of CD95 that 
abrogates recruitment of FADD, sub-
sequent cleavage of caspase-8, and 
productive apoptotic signaling. In 
the related human condition, autoim-
mune lymphoproliferative syndrome 
(ALPS) (Bidere et al., 2006), ALPS 
type Ia patients carry dominant-neg-9, May 4, 2007 ©2007 Elsevier Inc. 447
ative mutations in CD95 and type Ib 
patients have mutations in CD95L, 
resembling mice with the lprcg and gld 
mutations, respectively. ALPS type II 
is caused by mutations in caspase-10, 
and ALPS type III patients (who show 
an in vitro defect in CD95-mediated 
apoptosis of T cells) have no known 
mutations in CD95, CD95L, caspase-
8, or caspase-10.
The autoimmune pathologies seen 
in the mutant mice and in human 
patients correlate with an in vitro 
assay in which pre-activated T cells 
undergo cell death upon restimula-
tion (a phenomenon called activa-
tion-induced cell death or AICD). 
This process, which affects mostly 
a CD95-expressing Th1 subset of 
CD4+ T cells (Devadas et al., 2006), is 
defective in T cells from CD95/CD95L 
mutant mice or from human ALPS 
patients. These observations led 
to the proposal that CD95 plays an 
essential role in lymphocyte home-
ostasis. However, after 18 years of 
CD95 research and numerous studies 
of other members of the TNF receptor 
superfamily, we propose that CD95 
may have elaborate tissue-specific 
functions including, but not limited to, 
the induction of apoptosis. Increas-
ing evidence suggests that not only 
CD95 but also CD95L contributes to 
nonapoptotic functions of the CD95/
CD95L system through “retrograde” 
or “reverse” signaling. In this situa-
tion, the receptor CD95 acts as a lig-
and for the membrane-bound form of 
CD95L. For example, in activated T 
cells expressing CD95L, CD95L can 
transduce signals and together with 
antigen-mediated activation of the T 
cell receptor helps to drive T cell pro-
liferation (Sun et al., 2006).
Nonapoptotic Consequences of 
CD95 Signaling
Nearly all CD95-specific reagents 
were selected (or designed) because 
of their ability to induce apoptosis. 
None of the available CD95L prepara-
tions have the exact primary structure 
of the physiological soluble (sCD95L) 
or membrane-bound (mCD95L) lig-
and. They are either tagged (e.g., 
with FLAG) or are fusion proteins 
(e.g., leucine zipper CD95L). Recent 448 Cell 129, May 4, 2007 ©2007 Elseviwork shows that neither physiological 
sCD95L nor mCD95L efficiently kills 
certain cells that are readily killed 
by commercial anti-CD95 reagents, 
suggesting that in vivo CD95L may 
have nonapoptotic as well as apop-
totic activities (Algeciras-Schimnich 
et al., 2003). Consistent with this, 
there are data suggesting that CD95 
expressed on T and B cells does not 
just mediate apoptosis, at least not 
in a situation of an acute immune 
response. Loss of CD95 in either T 
or B cells or transgenic expression 
of a caspase inhibitor in these cells 
does not seem to cause an lpr-like 
syndrome (Chen et al., 2006; Hao et 
al., 2004). Thus, while CD95 is criti-
cal for AICD in vitro, the evidence to 
support its role in the acute death of 
activated T cells in vivo is less con-
vincing. Although there is indirect 
evidence that the lpr syndrome could 
be caused by resistance of CD95-
deficient dendritic cells to apoptosis 
(Chen et al., 2006), intrinsic apopto-
sis pathway components (such as the 
BH3 protein BIM) are more important 
than CD95 for apoptosis of T cells. 
So, what then is the function of the 
dramatic upregulation of CD95 by T 
cells shortly after activation? Sev-
eral studies demonstrate that T cell 
proliferation induced by suboptimal 
anti-CD3 stimulation is enhanced 
when CD95 is triggered (Alderson et 
al., 1993). Furthermore, deletion of 
CD95 in T cells causes lymphopenia 
in mice (Hao et al., 2004), suggest-
ing that CD95 expression by T cells 
is required for their survival, prolifera-
tion, and/or activation. Alternatively, 
CD95L, which is upregulated in T 
cells from these mice, could either 
generate an environment that does 
not allow naive T cells to survive or 
it could mediate nonapoptotic activi-
ties such as inducing proinflamma-
tory cytokine production in tissues 
expressing CD95 that then indirectly 
cause lymphopenia (Matsumoto et 
al., 2007).
The highest constitutive expres-
sion of CD95 is in liver cells (hepato-
cytes). Given that the anti-CD95 anti-
body Jo2 causes massive apoptosis 
of liver cells, CD95 was postulated 
to induce apoptosis of hepatocytes. er Inc.Liver cells also die through CD95-
mediated apoptosis during viral 
hepatitis, liver cirrhosis, and Wilson’s 
disease. However, CD95 is involved 
in liver regeneration subsequent to 
partial hepatectomy (Desbarats and 
Newell, 2000). Indeed, injection of 
the normally hepatotoxic Jo2 anti-
body into partially hepatectomized 
mice actually accelerates liver regen-
eration. Liver damage is associated 
with the activation of antiapoptotic 
signaling pathways (Akt, STAT3, and 
NF-κB) that protect against CD95-
mediated cell death and thus may 
help to switch CD95-mediated sig-
nals from primarily apoptotic to nona-
poptotic. While it is possible that the 
accelerated regenerative response 
caused by injection of Jo2 into par-
tially hepatectomized animals may be 
an indirect effect by an as yet uniden-
tified mechanism, these data strongly 
suggest a nonapoptotic activity for 
CD95 in the liver. Such findings on 
the function of CD95L/CD95 paral-
lel those for the TNF/TNFR1 system 
(Diehl, 2000).
CD95 is also widely expressed in 
the central nervous system (CNS). 
Neurons express CD95, and many 
CNS-derived tumor cells (such as 
glioblastoma) are sensitive to CD95-
mediated apoptosis in vitro. Sur-
prisingly, injection of CD95-specific 
monoclonal antibodies into mice with 
experimental sciatic nerve crush injury 
may actually accelerate functional 
recovery (Desbarats et al., 2003). In 
vitro, CD95 ligation induces neurite 
outgrowth in sensory neurons through 
activation of MAP kinases. The MAP 
kinase signaling pathway is activated 
in neural progenitor cells after CD95 
ligation (Tamm et al., 2004), and neu-
ronal branching in CNS neurons is 
stimulated by CD95 during develop-
ment both in vitro and in vivo (Zuliani 
et al., 2006). Thus, accumulating data 
suggest a physiologic role for CD95 
in regulating neuronal development, 
growth, differentiation, and regenera-
tion in the CNS. CD95 is also highly 
expressed and has been shown to 
mediate nonapoptotic activities in 
other tissues such as heart, pancreas, 
and colon (Badorff et al., 2002; Apos-
tolou et al., 2003).
Cell 129, May 4, 2007 ©2007 Elsevier Inc. 449Nonapoptotic, CD95-mediated sign-
aling promotes chronic inflammatory 
arthritis. The severity of disease in a 
DBA/1lpr/lpr mouse model of arthri-
tis induced by injection of collagen 
is markedly reduced compared to 
heterozygous controls despite the 
known resistance of lpr cells to apop-
tosis (Ma et al., 2004). Macrophages 
express both CD95 and CD95L; inter-
actions between CD95 receptors and 
the CD95L on adjacent macrophages 
leads to sequestration of FADD to 
the DISC complex but no apoptosis. 
Blocking CD95-CD95L interactions in 
cultured wild-type macrophages sup-
presses their activation by interleukin-1 
receptor 1 (IL-1R1) or toll-like receptor 
(TLR) 4 and the subsequent interaction 
of FADD with the TLR adaptor protein 
MyD88 (Ma et al., 2004). This sug-
gests that CD95-CD95L interactions 
may promote chronic inflammation 
through a unique mechanism in which 
CD95 ligation promotes activation via 
the IL-1R1–TLR4 pathway.
CD95 and CD95L in Cancer
Almost all human tumors express 
CD95. Increased expression of CD95L 
in solid tumors with concomitant down-
regulation of CD95 was interpreted 
as a way for tumor cells to mount a 
“counterattack” against tumor-infil-
trating lymphocytes (Green and Fer-
guson, 2001). The model is attractive 
because T cells are more sensitive to 
CD95-mediated apoptosis (in vitro) 
when activated and presumably would 
be killed by the tumor cells upon inter-
action with them. This “tumor strikes 
back” model was tested experimen-
tally by engineering tumors to express 
high levels of surface CD95L. Unex-
pectedly, these CD95L bearing tumors 
were often rejected more efficiently 
after injection into mice compared 
to their untransfected counterparts. 
Rejection of the tumors is largely 
independent of the adaptive immune 
system and is associated with rapid 
infiltration of neutrophils and other 
granulocytes. In addition, a variety 
of studies show that ligation of CD95 
expressed by tumor cells induces 
them to produce chemotactic factors 
such as IL-8 and MCP1 rather than 
undergo apoptosis, resulting in the recruitment of more proinflammatory 
cells thus linking CD95 to inflammation 
(Matsumoto et al., 2007). Many human 
cancers are associated with inflamma-
tion, which may in turn contribute to 
tumor growth. Thus, it is reasonable to 
hypothesize that in some cases CD95L 
via its interaction with CD95 could 
contribute to tumor growth in cancers 
associated with inflammation in part 
through the induction of chemotactic 
factors. Whether stimulation of cancer 
cells through CD95 leads to rejection 
of tumors or inflammation and tumor 
growth may depend on the tumor type 
and its stage of progression.
Tumor progression may be pro-
moted by nonapoptotic signals ema-
nating from CD95 that include (but 
are not limited to) activation of NF-κB 
and all three major MAPK pathways: 
ERK1/2, p38, and JNK1/2 (Barnhart et 
al., 2004). Activation of CD95 in apop-
tosis-resistant tumor cells results in the 
upregulation of a distinct set of genes 
whose products have been implicated 
in invasion, metastasis, and apoptosis 
resistance. Many tumor cells increase 
their motility and invasiveness in vitro 
when nonapoptotic pathways are acti-
vated through CD95, demonstrating 
that activation of these pathways is 
physiologically important.
An increase in the serum concen-
tration of sCD95L in cancer patients 
suggests a possible immunosuppres-
sive role for this molecule (although it 
is not clear whether the sCD95L exists 
in the biologically active trimerized 
form) (Barnhart et al., 2004). However, 
the generalized immune suppression 
that would be expected from this sit-
uation (rather than specific suppres-
sion of the immune response to the 
tumor) is not seen in these patients, 
and thus it may be that the increase 
in CD95L expression in tumor tissues 
plays a more direct role in tumor pro-
gression. CD95 has been reported to 
act as a tumor promotor in lung can-
cer (Lee et al., 2003), thyroid cancer 
(Mitsiades et al., 2006), and ovarian 
cancer (M.E.P., unpublished data).
CD95-Linked Signaling Pathways
Surprisingly little is known about the 
molecular links that connect CD95 to 
activation of the ERK, JNK, p38, and NF-κB signaling pathways. FADD, 
caspase-8, and c-FLIP (components 
of DISC) are known to link CD95 to 
nonapoptotic pathways (Matsumoto 
et al., 2007). A number of mouse 
models and mutant mice reveal non-
apoptotic activities for these DISC 
components (for review see Park et 
al., 2005). FADD, caspase-8, and c-
FLIP are essential for mice to develop 
beyond embryonic day 11.5, and 
studies now show that all three pro-
teins are important for the survival of 
activated T and B cells. In addition, 
both caspase-8 (Ben Moshe et al., 
2007) and FADD (Schuchmann et 
al., 2005) are required for effective 
liver regeneration. There is evidence 
that CD95 can be connected to the 
nonapoptotic activities of these DISC 
components. Both FADD and cas-
pase-8 are required for proliferation 
of early bone marrow-derived hemat-
opoietic progenitor cells (Pellegrini et 
al., 2005), and CD95L can protect this 
cell population from dying (Josefsen 
et al., 1999). Whether the DISC com-
ponents act through CD95, through 
other death receptor family mem-
bers, or independently of surface 
receptors is unknown, but the find-
ings emphasize that the downstream 
components of apoptosis can also 
play a role in lymphocyte or hepato-
cyte survival.
The ability of CD95 signaling to 
mediate either death or growth signals 
and to play a critical role in develop-
ment pathways may hinge on its abil-
ity to regulate downstream caspase 
activation. A reasonable candidate for 
mediating the regulation of signaling 
consequences may be c-FLIP, which 
at high concentrations can inhibit 
CD95-mediated apoptosis (for review 
see Park et al., 2005). Another possi-
ble switch between proapoptotic and 
nonapoptotic CD95 signaling may be 
the posttranslational modifications 
that regulate the ability of CD95 to 
become internalized after its activa-
tion by CD95L. Two acceptor sites for 
posttranslational modifications in the 
intracellular domain of CD95 regu-
late nonapoptotic activities of CD95. 
Tyr291 is important for internalization 
of CD95 (Lee et al., 2006), and Cys199 
regulates receptor aggregation and 
localization to lipid rafts, both requisite 
steps for CD95 internalization (Chakra-
bandhu et al., 2006). Internalization of 
CD95 into an endosomal compart-
ment may determine which signaling 
pathways are engaged. When inter-
nalization of CD95 is blocked, the 
receptor cannot induce apoptosis and 
instead remains fully engaged in acti-
vating nonapoptotic pathways (Lee et 
al., 2006). CD95 therefore seems to be 
similar to other internalizing receptors 
such as the epidermal growth factor 
receptor (EGFR). Internalization of 
EGFR targets activated receptors to 
the endocytic compartment and con-
tributes to both the intensity of sign-
aling and the assembly of signaling 
complexes (Miaczynska et al., 2004).
What mechanism decides which 
signaling pathways will be activated by 
CD95? It is likely that multiple signaling 
pathways, including those activated by 
caspases and NF-κB, are simultane-
ously triggered by ligation of CD95, and 
that only under certain conditions is the 
signaling threshold to induce apopto-
sis reached. Alternatively, nonapop-
totic outcomes may result in response 
to, for example, inhibition at the recep-
tor level (e.g., by c-FLIP), inappropriate 
concentrations of caspase-8/caspase-
10 or of downstream proapoptotic 
proteins such as Bax, upregulation of 
protective molecules (e.g., Bcl-2 or IAP 
family members), or activation of pro-
tective pathways (e.g., ERK, NF-κB).
Another mechanism for nonap-
optotic pathways to prevail may be 
through mutation or downregulation of 
CD95 itself, a situation frequently found 
in many human cancers (Muschen 
et al., 2000) enabling them to evade 
destruction by the immune system. 
However, tumor cells rarely completely 
lose CD95 expression and so may be 
able to regulate this receptor to estab-
lish a level of CD95 signaling that is too 
weak to induce receptor internaliza-
tion and apoptosis when engaged by 
CD95L but still sufficient for full activa-
tion of nonapoptotic pathways, which 
could lead to tumor promotion.
Conclusion
We suggest it is time to reappraise 
the physiological functions of the 
death receptor CD95 in various tis-450 Cell 129, May 4, 2007 ©2007 Elsevsues. We argue that important func-
tions of CD95 have been widely 
ignored and that the available data 
do not support the conclusion that 
the induction of apoptosis is the sole 
function, or perhaps, in some tis-
sues, even the primary function, of 
CD95 in vivo. Indeed, in some cases 
CD95 can act as a protector of tis-
sues rather than as their destroyer. 
Next, we need to identify the signal-
ing components that connect CD95 
to nonapoptotic signaling pathways 
because these may provide new 
targets to treat diseases, such as 
inflammation and cancer, for which 
nonapoptotic activities of CD95 are 
proving important.
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